| Biomarker ID | 971 |
| PMID | 22887127 |
| Year | 2012 |
| Biomarker | miR-375; miR-141; miR-378*; miR-409-3p |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Low Risk PCa: [miR-375 ; miR-141]; Downregulated in Low Risk PCa: [miR-378*, miR-409-3p] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(miRNA- 375):-DNA-binding transcription factor activity, RNA polymerase II-specific; DNA-binding transcription factor activity; nuclear chromatin; chromatin; nuclear chromosome Pathways Include(miRNA-141):- regulation of RNA metabolic process; Gene expression (Transcription); RNA Polymerase II Transcription; nuclear chromosome; DNA-binding transcription factor activity, RNA polymerase II-specific Pathways Include(miR-378):- anatomical structure morphogenesis; synapse; DNA binding; negative regulation of gene expression; cell morphogenesis |
| Experiment | Normal Vs Low Risk Prostate Cancer |
| Type of Biomarker | Prognostic |
| Cohort | 28 patients with Localized low risk, 30 with Localized high risk, and 26 with Metastatic Castration Resistant Prostate Cancer were selected for the study. Normal prostate tissue (n = 28), low-risk, localized prostate tumors (n = 42), and metastases (n = 14) were used for validation. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | miR-375; miR-141; miR-378*[p<0.0001]; miR-409-3p [p=0.004] |
| Method Used | NA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent dataset |
| Technical Name | miR-375, miR-141, miR-378*, miR-409-3p |